Molecular markers and biological targeted therapies in metastatic colorectal cancer: expert opinion and recommendations derived from the 11th ESMO/World Congress on Gastrointestinal Cancer, Barcelona, 2009

E. Van Cutsem*, M. Dicato, N. Arber, J. Berlin, A. Cervantes, F. Ciardiello, A. De Gramont, E. Diaz-Rubio, M. Ducreux, R. Geva, B. Glimelius, R. Glynne Jones, A. Grothey, T. Gruenberger, D. Haller, K. Haustermans, R. Labianca, H. J. Lenz, B. Minsky, B. NordlingerA. Ohtsu, N. Pavlidis, P. Rougier, W. Schmiegel, C. Van de Velde, H. J. Schmoll, A. Sobrero, J. Tabernero

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

Abstract

The article summarizes the expert discussion and recommendations on the use of molecular markers and of biological targeted therapies in metastatic colorectal cancer (mCRC), as well as a proposed treatment decision strategy for mCRC treatment. The meeting was conducted during the 11th ESMO/World Gastrointestinal Cancer Congress (WGICC) in Barcelona in June 2009. The manuscript describes the outcome of an expert discussion leading to an expert recommendation. The increasing knowledge on clinical and molecular markers and the availability of biological targeted therapies have major implications in the optimal management in mCRC.

Original languageEnglish
Pages (from-to)vi1-vi10
JournalAnnals of Oncology
Volume21
DOIs
StatePublished - Jun 2010
Externally publishedYes

Fingerprint

Dive into the research topics of 'Molecular markers and biological targeted therapies in metastatic colorectal cancer: expert opinion and recommendations derived from the 11th ESMO/World Congress on Gastrointestinal Cancer, Barcelona, 2009'. Together they form a unique fingerprint.

Cite this